Enanta Pharmaceuticals (ENTA) vs Prelude Therapeutics (PRLD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Prelude Therapeutics (PRLD) has outperformed Enanta Pharmaceuticals (ENTA) over the past year, gaining 173.2% versus a gain of 7.1%. Over five years, PRLD leads with a -76.1% price change compared with -83.1% for ENTA. Enanta Pharmaceuticals is the larger company by market cap ($352.4 million vs $309.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ENTA | PRLD |
|---|---|---|
| Share price | $12.10 | $3.88 |
| Market cap | $352.42M | $309.64M |
| 1-day change | -2.18% | +1.31% |
| YTD return | -23.27% | +33.79% |
| 1-year return | +7.08% | +173.24% |
| 5-year return | -83.07% | -76.14% |
| EPS (TTM) | $-2.42 | $-0.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.15 | $6.83 |
| 52-week low | $10.20 | $1.15 |
| Distance from 52-week high | -29.45% | -43.19% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +80.41% | +137.11% |
| Average volume | 228.45K | 479.23K |
| Shares outstanding | 29.13M | 65.08M |
| Employees | 120 | 79 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PRLD has outperformed ENTA by 166.2 percentage points over the past year.
About Enanta Pharmaceuticals
ENTA stock →Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 120 employees
About Prelude Therapeutics
PRLD stock →Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET.
Health Care · Biotechnology: Pharmaceutical Preparations · 79 employees
ENTA vs PRLD FAQ
Which is bigger, Enanta Pharmaceuticals or Prelude Therapeutics?
Enanta Pharmaceuticals (ENTA) is larger, with a market capitalization of $352.42M compared with $309.64M for Prelude Therapeutics (PRLD).
Which stock has performed better over the past year, ENTA or PRLD?
PRLD returned +173.24% over the past 12 months, compared with +7.08% for ENTA (price return, excluding dividends). Past performance does not predict future results.
Are Enanta Pharmaceuticals and Prelude Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.